79 research outputs found
Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques
Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells
Dendritic cells (DC) can achieve cross-presentation of naturally-occurring
tumor-associated antigens after phagocytosis and processing of dying tumor
cells. They have been used in different clinical settings to vaccinate cancer
patients. We have previously used gamma-irradiated MART-1 expressing melanoma
cells as a source of antigens to vaccinate melanoma patients by injecting
irradiated cells with BCG and GM-CSF or to load immature DC and use them as
a vaccine. Other clinical trials have used IFN-gamma activated macrophage
killer cells (MAK) to treat cancer patients. However, the clinical use of
MAK has been based on their direct tumoricidal activity rather than on their
ability to act as antigen-presenting cells to stimulate an adaptive antitumor
response. Thus, in the present work, we compared the fate of MART-1 after
phagocytosis of gamma-irradiated cells by clinical grade DC or MAK as well
as the ability of these cells to cross present MART-1 to CD8+
T cells. Using a high affinity antibody against MART-1, 2A9, which specifically
stains melanoma tumors, melanoma cell lines and normal melanocytes, the expression
level of MART-1 in melanoma cell lines could be related to their ability to
stimulate IFN-gamma production by a MART-1 specific HLA-A*0201-restricted
CD8+ T cell clone. Confocal microscopy with Alexa Fluor®647-labelled
2A9 also showed that MART-1 could be detected in tumor cells attached and/or
fused to phagocytes and even inside these cells as early as 1 h and up to
24 h or 48 h after initiation of co-cultures between gamma-irradiated melanoma
cells and MAK or DC, respectively. Interestingly, MART-1 was cross-presented
to MART-1 specific T cells by both MAK and DC co-cultured with melanoma gamma-irradiated
cells for different time-points. Thus, naturally occurring MART-1 melanoma
antigen can be taken-up from dying melanoma cells into DC or MAK and both
cell types can induce specific CD8+ T cell cross-presentation
thereafter
Quand les anticorps rencontrent l’immunité antitumorale : fin de partie pour la cellule cancéreuse ?
L’homme qui a fait sauter le verrou de la réponse immune adaptative anti-tumorale
James P. Allison, né le 7 août 1948, est un immunologiste américain, récipendiaire en 2015 du Prix Albert-Lasker de la recherche médicale clinique pour la découverte et le développement d’une thérapie fondée sur l’utilisation d’un anticorps monoclonal qui permet de débloquer la réponse immunitaire pour combattre le cancer
médecine/sciences en 2022, une passion pour la recherche…
International audienceBackground Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. Methods Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PAR low) and cisplatin-resistant (PAR high) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. Results The infiltration of tumors by CD8 T and DC-LAMP + cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=−0.39, p=0.034 in LACC, R=−0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR high). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). Conclusions Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure
- …